Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States

References

• Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics 2004;22(Suppl 1):1-12
   PubMedGoogle Scholar
• Kremer JM, Dougados M, Emery P, Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:2263-2271
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 20 2006;144:865-76
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-1400
   PubMed Web of Science ®Google Scholar
• Mease PJ, Revicki DA, Szechinski J, Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. J Rheumatol 2008;35:20-30
   PubMed Web of Science ®Google Scholar
• Schiff M, Keiserman M, Codding C, Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-1103
   PubMed Web of Science ®Google Scholar
• Genovese MC, Becker JC, Schiff M, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-1123
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-2806
   PubMed Web of Science ®Google Scholar
• Orencia [package insert]: Bristol-Myers Squibb, 2008.
   Google Scholar
• Rituxan [package insert]: 2008
   Google Scholar
• Kobelt G. Thoughts on health economics in rheumatoid arthritis. Ann Rheum Dis 2007;66(Suppl 3):iii35-39
   PubMedGoogle Scholar
• Drummond MF, Schwartz JS, Jonsson B, Key principles for the improved conduct of health technology assessments for resource allocation decisions. Int J Technol Assess Health Care 2008;24:244-258
   PubMed Web of Science ®Google Scholar
• Vera-llonch M, Massarotti E, Wolfe F, Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. Rheumatology (Oxford) 2008;47:535-541
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Reynolds A, Conway P. Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (Oxford) 2004;43:62-72
   PubMed Web of Science ®Google Scholar
• Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002
   PubMed Web of Science ®Google Scholar
• Vera-Llonch M, Massarotti E, Wolfe F, Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. J Rheumatol 2008;35:1745-1753
   PubMed Web of Science ®Google Scholar
• Lawrence RC, Helmick CG, Arnett FC, Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-799
   PubMed Web of Science ®Google Scholar
• Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics 2006;24:1221-1232
   PubMed Web of Science ®Google Scholar
• Fries JF, Spitz PW, Young DY. The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales. J Rheumatol 1982;9:789-793
   PubMed Web of Science ®Google Scholar
• Choi HK, Seeger JD, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. Arthritis Rheum 2000;43:2316-2327
   PubMed Web of Science ®Google Scholar
• Choi HK, Seeger JD, Kuntz KM. A cost effectiveness analysis of treatment options for methotrexate-naive rheumatoid arthritis. J Rheumatol 2002;29:1156-1165
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care 1997;35:1095-1108.
   PubMed Web of Science ®Google Scholar
• Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008;58:3657-3664
   PubMedGoogle Scholar
• Weinstein MC, Siegel JE, Gold MR, Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996;276:1253-1258
   PubMed Web of Science ®Google Scholar
• Halpern EF, Weinstein MC, Hunink MG, Gazelle GS. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Decis Making 2000;20:314-322
   PubMed Web of Science ®Google Scholar
• Goldie SJ. Chapter 15: Public health policy and cost-effectiveness analysis. J Natl Cancer Inst Monogr 2003;102-110
   PubMedGoogle Scholar
• Stinnett AA, Paltiel AD. Estimating CE ratios under second-order uncertainty: the mean ratio versus the ratio of means. Med Decis Making 1997;17:483-489
   PubMed Web of Science ®Google Scholar
• Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006;12:555-569
   PubMed Web of Science ®Google Scholar
• Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-408
   PubMed Web of Science ®Google Scholar
• Clark W, Jobanputra P, Barton P, Burls A. Technology assessment report commissioned by the HTA programme on behalf of the National Institute for Clinical Excellence: the clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults. 2003; http://eprints.bham.ac.uk/32/1/Clark_W,_Anakinra.pdf
   Google Scholar
• Jobanputra P, Barton P, Bryan S, Burls A. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2002;6:1-110
   PubMedGoogle Scholar
• Kobelt G, Jönsson L, Young A, Eberhardt K. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (Oxford) 2003;42:326-335
   PubMed Web of Science ®Google Scholar
• Welsing PM, Severens JL, Hartman M, Modeling the 5-year cost effectiveness of treatment strategies including tumor necrosis factor-blocking agents and leflunomide for treating rheumatoid arthritis in the Netherlands. Arthritis Rheum 2004;51:964-973
   PubMed Web of Science ®Google Scholar
• Kobelt G, Lindgren P, Singh A, Klareskog L. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann Rheum Dis 2005;64:1174-1179
   PubMed Web of Science ®Google Scholar
• Brennan A, Bansback N, Nixon R, Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. Rheumatology (Oxford) 2007;46:1345-1354
   PubMed Web of Science ®Google Scholar
• Wailoo AJ, Bansback N, Brennan A, Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis. Arthritis Rheum 2008;58:939-946
   PubMed Web of Science ®Google Scholar
• Saag KG, Teng GG, Patkar NM, American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784
   PubMed Web of Science ®Google Scholar
• Wolfe F, Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford) 2005;44(Suppl 4):iv18-22
   PubMedGoogle Scholar
• Genovese MC, Schiff M, Luggen M, Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547-554
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Results of a two-year follow-up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953-963
   PubMed Web of Science ®Google Scholar
• Genant HK, Peterfy CG, Westhovens R, Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis 2008;67:1084-1089
   PubMed Web of Science ®Google Scholar
• Westhovens R, Kremer JM, Moreland LW, Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. J Rheumatol 2009;36:736-742
   PubMed Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Emery P, Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum 2007;56:3896-38108
   PubMed Web of Science ®Google Scholar
• Keystone E, Emery P, Peterfy CG, Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009;68:216-221
   PubMed Web of Science ®Google Scholar
• Pincus T, Yazici Y, van Vollenhoven R. Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for long-term observations in standard care to complement clinical trials J Rheumatol 2006;33:2372-2375
   Google Scholar